SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alchemy Pay

Alchemy Pay is trending amid strong community debate, fueled by recent developments including new Money Transmitter Licenses, expanding fiat on-ramps for major stablecoins like Ripple's RLUSD, and the introduction of tokenized stock access. Many see it as a "sleeping giant" poised for a significant structural upgrade with its evolving Alchemy Chain, while others remain skeptical, viewing it as a "pump and dump" despite its growing global payment utility.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MULN CRYPTO is trending amidst highly polarized community sentiment, with many investors connecting the token to the controversial history of the original Mullen Automotive stock, citing past dilution and alleged misleading practices. While a "Mullen Army" promotes the token as a community-driven project with utility, a dominant conversation points to concerns about it being a "scam coin" or "rug pull" due to extremely low trading activity and perceived lack of intrinsic value. The narrative is heavily influenced by ongoing discussions around a class-action settlement related to the stock's history, fueling widespread skepticism.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is gaining significant attention due to its prominent partnership with World Liberty Finance and the impending rollout of its Super App, alongside confirmed integration with Stellar and ongoing discussions with Ripple. The community is highly optimistic, emphasizing ZBCN's robust real-world utility in payment and payroll infrastructure, its ISO 20022 and MiCA compliance, and its potential to become a foundational project in the real-world asset (RWA) sector. Many foresee substantial long-term growth, comparing its current positioning to that of early major cryptocurrencies.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending due to recent positive advancements in its HIV pipeline, including favorable trial results for a new regimen and extending market exclusivity for a leading therapy. This comes as the company continues to strategically bolster its oncology and antiviral assets, driving increased analyst interest and discussions around its diversified growth trajectory.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is generating significant buzz due to the recent pardon of Binance founder CZ, which has ignited fresh optimism within the community. Traders are closely monitoring technical indicators, actively discussing potential price rallies and short-term movements. This renewed interest is further amplified by ongoing ecosystem developments, such as new integrations and consistent token burns, reinforcing BNB's utility.

BlackPearl.Chain is pushing decentralization into the future with a third-generation public blockchain. It’s network achieves blazing transaction speeds (Millions TPS) using Sharding and a VRF lightning-fast consensus mechanism built in-house. Finality is achieved in under three seconds with revolutionary P2P, Its speed and security make it the perfect platform for applications like digital asset trading, social media messaging, payment processing, supply chain tracking, and other high-scale use cases.

BlackPearl

The BPLC crypto community is highly optimistic about its long-term potential, with many envisioning it as a future "game changer" in commerce. Enthusiastic investors are comparing it to established digital assets like XRP, eagerly anticipating mainstream exchange adoption and significant market cap expansion.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSky Technology is trending following a bullish analyst initiation and a significant new multi-year international defense contract, positioning it as a key player in the rapidly expanding space and defense intelligence sector. Community discussion highlights the company's advanced AI-enabled, high-resolution satellite imagery for tactical military use and its significant long-term growth potential, despite ongoing conversations about satellite launch timelines and market volatility.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed reactions to interim Phase 2 data for its cystic fibrosis therapy, ARCT-032, leading to significant volatility as some view the stock's sharp decline as an overreaction to early biological activity like mucus plug reduction. The community is actively discussing the potential of higher dose cohorts, progress in their OTC deficiency program, and an ongoing trade secret lawsuit against AbbVie, all while anticipating future pipeline developments and a potential short squeeze.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian ($TEAM) is trending as the broader software sector experiences significant pressure, driven by fears of AI disruption to core offerings like Jira and Confluence. While many in the community perceive the downturn as an overreaction and a buying opportunity given the company's solid fundamentals and AI integration efforts, concerns about continued weakness and insider selling persist among others.

Avino Silver & Gold Mines Ltd. engages in the mining and exploration activities. It focuses on silver reserves in the Durango region of North Central Mexico. It operates through the Silver, Gold, and Copper segments. The company was founded on May 15, 1968 and is headquartered in Vancouver, Canada.

Avino Silver & Gold Mines Ltd.

Avino Silver & Gold Mines is currently trending amidst widespread bullish sentiment for precious metals, with many in the community anticipating a significant silver price breakout driven by physical demand and perceived market manipulation. Investors are keenly focused on ASM's strong operational performance, upcoming La Preciosa project developments, and solid earnings, expecting a substantial re-rating for the stock to reflect surging metal prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat...

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, MarketBeat reports. One...

Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC

Stonepine Capital Management LLC boosted its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 19.3% in the second quarter, according to the company in its most recent Form...

Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 3.8% - Here's Why

Zevra Therapeutics (NASDAQ:ZVRA) Trading Up 3.8% - Should You Buy...

Campbell & CO Investment Adviser LLC Buys Shares of 83,245 Zevra Therapeutics, Inc. $ZVRA

Campbell & CO Investment Adviser LLC purchased a new position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the second quarter, according to its most recent Form 13F filing with the...

Los Angeles Capital Management LLC Buys Shares of 121,225 Zevra Therapeutics, Inc. $ZVRA

Los Angeles Capital Management LLC purchased a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F...

Research Analysts Set Expectations for ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings estimates for Zevra Therapeutics in a research report issued to clients and...

FY2025 EPS Estimate for Zevra Therapeutics Raised by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities researchers at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to...

William Blair Analysts Boost Earnings Estimates for ZVRA

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - William Blair lifted their Q3 2026 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a report issued on Wednesday, November...

FY2026 EPS Estimates for ZVRA Decreased by Cantor Fitzgerald

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2026 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on...

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Current Price	$8.93
Prev Close	$9.02
Open	$9.00
Dividend Yield	0.00%
50-Day Moving Average	$8.73
Beta	0.88
Avg. Volume	956,384.59
PE Ratio	14.16

52-Week High	$13.16
52-Week Low	$6.19
Market Capitalization	$502.74M
EPS (Annual)	-$2.28
Price to Book	3.77
Revenue Per Employee	$400,203.39
Enterprise Value/EBITDA	N/A

ZVRA
Zevra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZVRA News

ZVRAZevra Therapeutics Inc